In This Section
SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy
SNMMI assembled an autonomous Workgroup to represent a multidisciplinary panel of health care providers with substantive knowledge in the use of nuclear medicine in 177Lu-PSMA-617 Radionuclide Therapy to review the scientific literature and develop consensus recommendations for the clinical use of this technology. The working group conducted a systematic review of existing evidence based on the scope and parameters. The systematic review was used to make their recommendations for clinical use.
To view the development process, please click the following link: SNMMI AUC Development Process.